What Eightco Holdings Inc.’s unusual AI-crypto-creator strategy could signal for the next wave of digital platforms (NASDAQ: ORBS)
Eightco Holdings Inc. secures $125M to invest across AI, blockchain, and creator platforms. Discover what this unusual strategy could mean for digital platforms.
Adobe’s $26bn recurring revenue base signals durable software demand in AI era (NASDAQ: ADBE)
Adobe posts $6.4B quarterly revenue and $26B recurring revenue as AI tools drive subscription growth. Discover what this means for investors and the software market.
Can iSpecimen Inc.’s AI-powered biospecimen matching agent accelerate precision research workflows? (NASDAQ: ISPC)
Discover how iSpecimen Inc.’s new AI biospecimen matching agent could transform research sample sourcing and accelerate precision medicine studies.
NU E Power Corp rescinds Blu Dot acquisition agreement — what it means for investors in 2026 (CSE: NUE)
NU E Power Corp rescinds its Blu Dot acquisition and cancels 29.5M shares. Find out what this strategic reset means for investors in 2026.
Why the Palantir Technologies–NVIDIA sovereign AI stack matters for latency, security, and data control (NASDAQ: PLTR, NASDAQ: NVDA)
Discover how Palantir Technologies and NVIDIA are building a sovereign AI infrastructure stack that gives enterprises control over data, latency, and AI deployment.
Why ArcLight is buying InfraBridge’s stake in Invenergy’s 5.4 GW North American power portfolio
ArcLight acquires InfraBridge’s stake in a 5.4 GW Invenergy power portfolio. Discover why reliable electricity generation is gaining importance in the AI era.
Could Ondas Inc. and World View give Palantir Technologies its next major defense AI wedge? (NASDAQ: PLTR, NASDAQ: ONDS)
Discover how Palantir, Ondas, and World View are building a multi-domain intelligence platform and why it could reshape defense AI systems.
Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?
Could subcutaneous PD-1 therapy reshape cancer treatment in China? Explore Junshi Biosciences’ toripalimab filing and its impact on oncology logistics.
The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)
Veru Inc. launches the Phase 2b PLATEAU trial combining enobosarm with semaglutide. Discover what this could mean for the $100B obesity drug market.
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.